Product Name: CARMA3 Antibody
Species Reactivity: Human
Tested Applications: ELISA, IHC-P
Applications: CARMA3 antibody can be used for detection of CARMA3 by immunohistochemistry at 5 μg/mL.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight:
Immunogen: CARMA3 antibody was raised against a 16 amino acid synthetic peptide near the amino terminus of human CARMA3.The immunogen is located within the first 50 amino acids of CARMA3.
Host Species: Rabbit
Purification: CARMA3 Antibody is affinity chromatography purified via peptide column.
Physical State: Liquid
CAS NO.: 946518-61-2
Product: LY2409881
Buffer: CARMA3 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Conditions: CARMA3 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: CARMA3 Antibody: BIMP1, CARMA3, Caspase recruitment domain-containing protein 10, CARD-containing MAGUK protein 3, Carma 3
Accession NO.: NP_055365
Protein Ino: 51093861
Official Symbol: CARD10
Geneid: 29775
Background: CARMA3 Antibody: CARMA proteins belong to the membrane-associated guanylate kinase-like (MAGUK) family of proteins that can function as molecular scaffolds that assist assembly of signal transduction molecules. CARMA1, CARMA2, and CARMA3 share high degrees of sequence and functional homology, but their tissue-specific distribution suggests that they serve distinct biological functions in different cell types. As with CARMA1, the CARD domain of CARMA3 has been shown to specifically interact with BCL10, a protein known to function as a positive regulator of cell apoptosis and NF-κB activation. When expressed in cells, this protein binds to BCL10 and activates NF-κB Recent experiments have shown that CARMA3 is required for EGF-induced NF-κB activation and contributes to tumor growth in vivo, suggesting that CARMA3 may serve as a new therapeutic target for the treatment of EGFR-driven tumors.
PubMed ID:http://aac.asm.org/content/43/4/969.abstract
